TY - JOUR
TI - Ixazomib-lenalidomide-dexamethasone in routine clinical practice: Effectiveness in relapsed/refractory multiple myeloma
AU - Hájek, R.
AU - Minarík, J.
AU - Straub, J.
AU - Pour, L.
AU - Jungova, A.
AU - Berdeja, J.G.
AU - Boccadoro, M.
AU - Brozova, L.
AU - Spencer, A.
AU - Van Rhee, F.
AU - Vela-Ojeda, J.
AU - Thompson, M.A.
AU - Abonour, R.
AU - Chari, A.
AU - Cook, G.
AU - Costello, C.L.
AU - Davies, F.E.
AU - Hungria, V.T.M.
AU - Lee, H.C.
AU - Leleu, X.
AU - Puig, N.
AU - Rifkin, R.M.
AU - Terpos, E.
AU - Usmani, S.Z.
AU - Weisel, K.C.
AU - Zonder, J.A.
AU - Barinová, M.
AU - Kuhn, M.
AU - Šilar, J.
AU - Cápková, L.
AU - Galvez, K.
AU - Lu, J.
AU - Elliott, J.
AU - Stull, D.M.
AU - Ren, K.
AU - Maisnar, V.
JO - Future Oncology
PY - 2021
VL - 17
TODO - 19
SP - 2499-2512
PB - Future Medicine Ltd
SN - 1479-6694, 1744-8301
TODO - 10.2217/fon-2020-1225
TODO - dexamethasone;  ixazomib;  lenalidomide;  antineoplastic agent;  boron derivative;  dexamethasone;  glycine;  ixazomib;  lenalidomide, adult;  aged;  Article;  cancer recurrence;  clinical outcome;  clinical practice;  controlled study;  data analysis;  data integration;  diarrhea;  drug dose reduction;  drug efficacy;  drug response;  drug safety;  drug withdrawal;  fatigue;  female;  follow up;  human;  infection;  major clinical study;  male;  middle aged;  multiple myeloma;  neuropathy;  neutropenia;  observational study;  overall response rate;  progression free survival;  thrombocytopenia;  time to treatment;  clinical trial;  drug resistance;  mortality;  multicenter study;  multiple myeloma;  pathology;  prospective study;  tumor recurrence;  very elderly, Adult;  Aged;  Aged, 80 and over;  Antineoplastic Combined Chemotherapy Protocols;  Boron Compounds;  Dexamethasone;  Drug Resistance, Neoplasm;  Female;  Glycine;  Humans;  Lenalidomide;  Male;  Middle Aged;  Multiple Myeloma;  Neoplasm Recurrence, Local;  Progression-Free Survival;  Prospective Studies
TODO - Aim: To evaluate the effectiveness and safety of ixazomib-lenalidomide-dexamethasone (IRd) in relapsed/refractory multiple myeloma in routine clinical practice. Patients & methods: Patient-level data from the global, observational INSIGHT MM and the Czech Registry of Monoclonal Gammopathies were integrated and analyzed. Results: At data cut-off, 263 patients from 13 countries were included. Median time from diagnosis to start of IRd was 35.8 months; median duration of follow-up was 14.8 months. Overall response rate was 73%, median progression-free survival, 21.2 months and time-to-next therapy, 33.0 months. Ixazomib/lenalidomide dose reductions were required in 17%/36% of patients; 32%/30% of patients discontinued ixazomib/lenalidomide due to adverse events. Conclusion: The effectiveness and safety of IRd in routine clinical practice are comparable to those reported in TOURMALINE-MM1. Clinical trial registration: NCT02761187 (ClinicalTrials.gov)</ext-link. © 2021 Future Medicine Ltd.. All rights reserved.
ER -